Related references
Note: Only part of the references are listed.Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 x 2, Phase II Trial
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial
Agnieszka Wierzbowska et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Hartmut Doehner et al.
LEUKEMIA (2018)
Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia
Lieke H. van der Helm et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes
Chun-Kang Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Elevated fetal haemoglobin is a predictor of better outcome inMDS/AML patients receiving 5-aza-2-deoxycytidine (Decitabine)
Michael Luebbert et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials
Stephen A. Strickland et al.
LEUKEMIA RESEARCH (2017)
Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy
Jan K. Hiller et al.
ANNALS OF HEMATOLOGY (2017)
Innovative strategies for adverse karyotype acute myeloid leukemia
Sabine Blum et al.
CURRENT OPINION IN HEMATOLOGY (2017)
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group
Michael Luebbert et al.
ANNALS OF HEMATOLOGY (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
Koichi Takahashi et al.
ONCOTARGET (2016)
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
Ashkan Emadi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)
Heiko Becker et al.
ANNALS OF HEMATOLOGY (2015)
Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
Hyun Ae Jung et al.
ONCOTARGET (2015)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics
Aziz Nazha et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia
Haiyang Yun et al.
HAEMATOLOGICA (2014)
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
Cecile Bally et al.
LEUKEMIA RESEARCH (2014)
Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells
Lan Yi et al.
ONCOTARGET (2014)
Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome
Hong Wang et al.
ANNALS OF HEMATOLOGY (2013)
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
Frank G. Rueckner et al.
BLOOD (2012)
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Michael Luebbert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
K. H. Metzeler et al.
LEUKEMIA (2012)
Aberrant Epigenetic and Genetic Marks Are Seen in Myelodysplastic Leukocytes and Reveal Dock4 as a Candidate Pathogenic Gene on Chromosome 7q
Li Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia
H. Seifert et al.
LEUKEMIA (2009)
Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype
Dimitri A. Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype
C. Haferlach et al.
LEUKEMIA (2008)
The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine
M Nieto et al.
ONCOGENE (2004)
Share Paper
